2 weeks Ago By Defense World Staff
Teacher Retirement System of Texas increased its holdings in shares of ADMA Biologics, Inc. ( NASDAQ:ADMA – Free Report ) by 25.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission.
The firm owned 69,044 shares of the biotechnology company’s stock after purchasing an additional 13,811 shares during the period. Teacher Retirement System of Texas’ holdings in ADMA Biologics were worth $1,184,000 as of its most recent filing with the Securities and Exchange Commission. Several other large investors have also recently added to or reduced their stakes in ADMA.
Oregon Public Employees Retirement Fund lifted its position in shares of ADMA Biologics by 1.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock worth $954,000 after purchasing an additional 700 shares in the last quarter.
Mutual of America Capital Management LLC lifted its holdings in ADMA Biologics by 2.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock worth $614,000 after buying an additional 751 shares in the last quarter.
Maryland State Retirement & Pension System lifted its holdings in ADMA Biologics by 1.1% in the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock worth $1,365,000 after buying an additional 897 shares in the last quarter.
GAMMA Investing LLC boosted its position in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 967 shares during the last quarter.
Finally, State of Alaska Department of Revenue grew its stake in shares of ADMA Biologics by 1.0% during the fourth quarter. State of Alaska Department of Revenue now owns 134,346 shares of the biotechnology company’s stock valued at $2,304,000 after acquiring an additional 1,337 shares in the last quarter.
75.68% of the stock is currently owned by institutional investors and hedge funds. ADMA Biologics Price Performance Shares of ADMA stock opened at $20.
26 on Friday. The firm has a fifty day moving average of $17.13 and a two-hundred day moving average of $18.
15. The firm has a market cap of $4.79 billion, a P/E ratio of 72.
36 and a beta of 0.60. ADMA Biologics, Inc.
has a 1-year low of $5.90 and a 1-year high of $23.64.
The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.
26. Wall Street Analysts Forecast Growth Get Our Latest Stock Analysis on ADMA Biologics ADMA Biologics Profile ( Free Report ) ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles Five stocks we like better than ADMA Biologics What Investors Need to Know to Beat the Market MarketBeat Week in Review – 03/24 – 03/28 Industrial Products Stocks Investing Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low How to Invest in Biotech Stocks 4 Healthcare Stocks With Massive Gains—and More to Come Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter ..
